AI Summary & Key Takeaways
AI InsightCD105 isa potentially reliable marker for the immunohistochemical grading of EF, in contrast to OPN.
📌 3 Key Takeaways
Özet
AIM: To evaluate bevacizumab for epidural fibrosis (EF) treatment in an experimental rat model using histopathology as well asimmunohistochemical staining for CD105 and osteopontin (OPN).MATERIAL and METHODS: Sixteen Wistar Albino rats underwent either laminectomy alone to induce EF (group I, control) orlaminectomy plus local bevacizumab treatment (group II). The degree of EF was compared between groups using the currenthistopathological grading method as well as immunohistochemistry for CD105 and OPN. In addition, the consistency of EF stagingusing CD105 and OPN expression was compared to that using histopathology.RESULTS: The grade of EF was significantly lower in group II than in group I based on the fibroblast count and fibrosis densitydetermined using histopathology, as well as by CD105 expression determined using immunohistochemistry. In contrast, OPNexpression was not a reliable marker for EF evaluation because it did not show a significant difference between the two groups.CONCLUSION: Bevacizumab prevents EF development as assessed using both histopathology and CD105 expression. CD105 isa potentially reliable marker for the immunohistochemical grading of EF, in contrast to OPN.